Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone

Biochemical Pharmacology

Volumn 58, Issue 4, 1999, Pages 703-708

  Vance, John R ^a,b   Bastow, Kenneth F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acridone; Antiviral; Catalytic inhibitor; DNA topoisomerase II

Indexed keywords

1,3,7 TRIHYDROXYACRIDONE; 7 CHLORO 1,3 DIHYDROXYACRIDONE; ACRIDONE DERIVATIVE; AMSACRINE; ANTIVIRUS AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DNA BINDING; DNA DENATURATION; ENZYME INHIBITION; PRIORITY JOURNAL;

ACRIDINES; AMSACRINE; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CATALYSIS; DNA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; PLASMIDS;

EID: 0033567433     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00140-9     Document Type: Article

References (20)

1. Wang J.C. DNA topoisomerases. Annu Rev Biochem. 65:1996;635-692.
2. Kreuzer K.N. DNA topoisomerases as potential targets of antiviral action. Pharmacol Ther. 43:1989;377-395.
3. Maschera B., Ferrazzi M., Rassu M., Toni M., Palu G. Evaluation of topoisomerase inhibitors as potential antiviral agents. Antiviral Chem Chemother. 4:1993;85-91.
4. Shen L.L., Fostel J.M. DNA topoisomerase inhibitors as antifungal agents. Adv Pharmacol. 29B:1994;227-244.
5. Chen A.Y., Liu L.F. DNA topoisomerases Essential enzymes and lethal targets . Annu Rev Pharmacol Toxicol. 34:1994;191-218.
6. Sørensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westergaard O. Mode of action of topoisomerase II-targetting agents at a specific DNA sequence Uncoupling the DNA binding, cleavage and religation events . J Mol Biol. 228:1992;778-786.
7. Fortune J.M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem. 273:1998;17643-17650.
8. Hoffmann G.A., Mirabelli C.K., Drake F.H. Quantitative adaptation of the bacteriophage P4 unknotting assay for use in the biochemical and pharmacological characterization of topoisomerase II. Anticancer Drug Des. 5:1990;273-282.
9. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA. 91:1994;1781-1785.
10. Kitanaka S., Yasuda I., Kashiwada Y., Hu C.-Q., Bastow K.F., Bori I.D., Lee K.-H. Antitumor agents, 162. Cell-based assays for identifying novel DNA topoisomerase inhibitors Studies on the constituents of Fatsia japonica . J Nat Prod. 58:1995;1647-1654.
11. Ferguson P.J., Fisher M.H., Stephenson J., Li D.-H., Zhou B.-S., Cheng Y.-C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 48:1988;5956-5964.
12. Bastow K.F., Itoigawa M., Furukawa H., Kashiwada Y., Bori I.D., Ballas L.M., Lee K.-H. Antiproliferative actions of 7-substituted 1,3-dihydroxyacridones; possible involvement of DNA topoisomerase II and protein kinase C as biochemical targets. Bioorg Med Chem. 2:1994;1403-1411.
13. Spitzner J.R., Chung I.K., Muller M.T. Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acids Res. 18:1990;1-11.
14. Pommier Y., Minford J.K., Schwartz R.E., Zwelling L.A., Kohn K.W. Effects of the DNA intercalators 4′-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry. 24:1985;6410-6416.
15. Liu L.F., Rowe T.C., Yang L., Tewey K.M., Chen G.L. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 258:1983;15365-15370.
16. Tewey K.M., Rowe T.C., Yang L., Halligan B.D., Liu L.F. Adriamycin-induced DNA damage mediated by DNA topoisomerase II. Science. 226:1984;466-468.
17. Pommier Y., Covey J., Kerrigan D., Mattes W., Markovits J., Kohn K.W. Role of DNA intercalation in the inhibition of purified mouse leukemia (L1210) DNA topoisomerase II by 9-aminoacridines. Biochem Pharmacol. 36:1987;3477-3486.
18. Chen M., Beck W.T. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 53:1993;5946-5953.
19. Corbett A.H., Hong D., Osheroff N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several cleavage-enhancing agents share a common site of action on the enzyme. J Biol Chem. 268:1993;14394-14398.
20. Elsea S.H., Westergaard M., Burden D.A., Lomenick J.P., Osheroff N. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry. 36:1997;2919-2924.